|
|
Article: Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting.
- Article from:
- PR Newswire
- Article date:
- September 2, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Results from studies related to Optimer Pharmaceuticals, Inc.'s lead developmental product candidates will be presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held at The Moscone Center in San Francisco on September 12-15, 2009.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
Fidaxomicin abstracts and speakers include:
"Low Recurrence Rate among Patients with C. difficile Infection (CDI)
Treated with Fidaxomicin (FDX)"
Poster Presentation: Yoav Golan, M.D., M.S.
Monday, September 14, 2009 11:15am-1:15pm Pacific Time
...